Development Pipeline
Patients Respond to Cancer Therapy in Different Ways. So Do We.
There are different kinds of cancer. That’s why we develop different kinds of cancer therapy, with the goal of making cancer more treatable for individual patients.
Our cancer drug development pipeline includes a biologically enhanced taxane, a new compound designed to treat cancers normally treated with anthracyclines, and a DNA minor groove binding agent—each of which has the potential to treat a variety of cancer types.
Current Status
We are focused on gaining approvals for our two phase III product candidates, pixantrone in relapsed or refractory aggressive non-Hodgkin’s lymphoma, and OPAXIO in maintenance therapy for ovarian cancer and as a radiation sensitizer in the treatment of esophageal cancer. We have one product in phase II clinical development, and other candidates in preclinical research. These products may address the therapeutic limitations of conventional cancer therapies.
other resources Clinical Trials Recent Scientific Presentations